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Raman profiles of the stratum corneum define 3 filaggrin
genotype–determined atopic dermatitis endophenotypes
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PhD,f,g W. H. Irwin McLean, DSc, FMedSci,d Peter J. Caspers, PhD,f,g* and Alan D. Irvine, MD, FRCPIa,b,h* Dublin, Ireland,
Rotterdam, The Netherlands, and Dundee, United KingdomBackground: Filaggrin (FLG) has a central role in the
pathogenesis of atopic dermatitis (AD). FLG is a complex
repetitive gene; highly population-specific mutations and
multiple rare mutations make routine genotyping complex.
Furthermore, the mechanistic pathways through which
mutations in FLG predispose to AD are unclear.
Objectives: We sought to determine whether specific Raman
microspectroscopic natural moisturizing factor (NMF)
signatures of the stratum corneum could be used as markers of
FLG genotype in patients with moderate-to-severe AD.
Methods: The composition and function of the stratum corneum
in 132 well-characterized patients with moderate-to-severe AD
were assessed by means of confocal Raman microspectroscopy
and measurement of transepidermal water loss (TEWL). These
parameters were compared with FLG genotype and clinical
assessment.
Results: Three subpopulations closely corresponding with FLG
genotype were identified by using Raman spectroscopy. The
Raman signature of NMF discriminated between FLG-
associated AD and non–FLG-associated AD (area under the
curve, 0.94; 95% CI, 0.91-0.99). In addition, within the subset of
FLG-associated AD, NMF distinguished between patients with
1 versus 2 mutations. Five novel FLG mutations were found on
rescreening outlying patients with Raman signatures suggestive
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subgroups.
Conclusions: Raman spectroscopy permits rapid and highly
accurate stratification of FLG-associated AD. FLGmutations do
not influence TEWL within established moderate-to-severe AD.
(J Allergy Clin Immunol 2010;126:574-80.)
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Atopic dermatitis (AD) is a complex and heterogeneous
inflammatory skin disease driven and modified by immunologic,
environmental, and genetic factors.1,2 The identification of filaggrin
(FLG) null alleles in up to 50% of patients with moderate-to-severe
ADimplicates a fundamental role forbarrier homeostasis in this dis-
ease.3-6 Although the mechanisms leading to AD in FLGmutation
carriers are unclear, the deficiency of FLG likely facilitates perme-
ability of biologically active allergens and microbial colonization
that subsequently trigger inflammatory cascades.7 The recent iden-
tification of a murine model for FLG deficiency, with the detection
of a homozygous frameshift mutation in the Flg gene in flaky tail
mice, should accelerate our understanding of pathogenic mecha-
nisms and therapeutic intervention points in patients with AD.8
Knowledge of the biochemical functions of filaggrin and its
breakdown products indicate that a quantitative variation in
gene or protein dosage might be relevant in determining pheno-
type.9,10 Filaggrin is initially produced as profilaggrin, a large, in-
soluble, heavily phosphorylated protein consisting of 10 to 12
tandem repeats of filaggrin units separated by short hydrophobic
linker peptides.11,12 In the transitional layer profilaggrin is de-
phosphorylated and proteolytically processed into its functional
filaggrin units, which bind to and collapse the keratin cytoskeleton
and other intermediate filaments, acting as a scaffold for the sub-
sequent reinforcement steps of the stratum corneum (SC).13-15
Subsequently, filaggrin is progressively degraded within the SC
into a pool of hygroscopic amino acids, including pyrrolidone car-
boxylic acid, urocanic acid, and alanine. This composite mixture
of amino acids and their derivatives, together with specific salts
and sugars, form the natural moisturizing factor (NMF).16,17
NMF is highly hygroscopic and plays a central role in
maintaining hydration of the SC and is additionally proposed to
have a significant role in maintenance of the pH gradient of the
skin, cutaneous antimicrobial defense, and regulation of key
J ALLERGY CLIN IMMUNOL
VOLUME 126, NUMBER 3
O’REGAN ET AL 575Abbreviations usedAD: Atopic dermatitisAUC: Area under the curveFLG: Filaggrin
HLP: Hyperlinear palmsNMF: Natural moisturizing factorROC: Receiver operating characteristicSC: Stratum corneumTEWL: Transepidermal water lossenzymatic events in the SC.18,19 Filaggrin thus has complex func-
tions, with roles in establishing structural and chemical barrier
function, hydration, and maintenance of epidermal homeostasis
in the face of continuous transformation.20 Expression of filaggrin
and subsequent breakdown of filaggrin into NMF is additionally
determined based on properties of the microenvironment, includ-
ing local pH, relative humidity, and protease activity.17,21,22 In
vitro evidence also indicates that filaggrin skin expression might
be modulated by the atopic inflammatory response mediated by
the cytokines IL-4 and IL-13.23 Genetically determined modifiers
of protein dosage include the copy number of filaggrin repeat units,
which vary in the population from 10 to 12 units and segregate by
normal Mendelian genetic mechanisms.11,24 These genetic poly-
morphisms reflect tandem duplications of FLG repeats 8, 10, or
both and might be an additional modifier of disease phenotype
in heterozygotes who carry longer-sized variants on the unaffected
allele.25 Our early data suggest that NMF levels correlate with
FLG-null allele status and might therefore directly contribute to
the dry skin phenotype seen in both patients with ichthyosis vulga-
ris and those with AD.10
Raman spectroscopy is capable of measuring in vivo informa-
tion regarding the molecular composition of the skin, including
quantitative analysis of amino acids and water content. It is based
on the inelastic light scattering, or Raman scattering, of mono-
chromatic light when the frequency of photons, usually from a
laser source, changes on interaction with a sample, giving rise
to characteristic Raman spectra and providing noninvasive real-
time signatures of biological samples at a molecular level.
We sought to determine whether specific Raman NMF signa-
tures of the SC could be used as markers of FLG genotype in
patients with moderate-to-severe AD. We examined the associa-
tion of NMF estimation with clinical evidence of hyperlinear
palms (HLP), a clinical sign that has been shown to be associated
with FLGmutations in previous studies. We also sought to exam-
ine the effects, within patients with moderate-to-severe AD, of
FLG genotype on transepidermal water loss (TEWL) as a
measure of an inside-out barrier defect.METHODS
Following standard genetic practice, in this articleFLG2/2 designates a pa-
tient homozygous for null alleles (ie, 2 null alleles), FLG1/2 designates a het-
erozygote null allele/wild-type (ie, 1 null allele), and FLG1/1 designates a
homozygote wild-type (ie, 0 null alleles). A further abbreviation describes pa-
tients with AD with FLG mutations (FLG1/2 and FLG2/2) as ADFLG and
those without FLG mutations (ie, FLG1/1) as ADNON-FLG.
One hundred thirty-five unrelated Irish children with a history of moderate-
to-severe AD were recruited from dedicated tertiary referral AD clinics.
Diagnosis was made by experienced pediatric dermatologists according to the
United Kingdom diagnostic criteria.26 Exclusion criteria from the study were
patients who had received systemic therapy, such as corticosteroids orimmunosuppressants, in the preceding 3 months and patients whose ancestry
was not exclusively Irish (4/4 grandparents). Detailed phenotypic data were
collected. The Nottingham Eczema Severity Score27 was selected as an esti-
mate of disease severity. Given previous publications and our own clinical ex-
perience of noting palmar hyperlinearity, this clinical signwas scored by using
an investigator assessment of 0 (no hyperlinearity), 1 (mild/subtle hyperlinear-
ity), and 2 (severe hyperlinearity).
Genetic screening
All patients were screened for the 6 most prevalent FLG mutations in the
Irish population (R501X, 2282del4, R2447X, S3247X, 3702delG, and
Y2092X), as previously described.28 Full sequencing of FLG was performed
as detailed previously.28 Based on screening for these 6 prevalent FLG muta-
tions, 58.3% were carriers of 1 or more FLG mutations (15.1% FLG2/2,
43.2% FLG1/2, and 41.7% FLG1/1). An additional rare mutation was known
to be present in 1 subject in a heterozygous state (R1474X). Additional screen-
ing was performed by means of complete sequencing of the FLG gene in se-
lected subjects, as previously described.29 The entire collection was then
rescreened for these 5 novel mutations found on complete sequencing.
Biophysical analysis of the SC
Skin biophysical measurements were performed under standardized con-
ditions (room temperature, 22 8C-25 8C; humidity levels, 30% to 35%). Before
measurements, patients were acclimatized for a minimum of 10 minutes. All
measurements were performed by one of 2 investigators (G.M.O. and
P.M.J.H.K.). Topical therapies, including emollients, were withheld from
the measurement sites for 48 hours preceding the study. TEWLwas measured
on nonlesional skin of the extensor forearm (Tewameter 300; Courage and
Khazaka Electronic GmbH, Cologne, Germany).
NMF was measured in the SC of the thenar eminence by using confocal
Raman microspectroscopy (model 3510 Skin Composition Analyzer; River
Diagnostics, Rotterdam, The Netherlands). The principles of this method and
the procedure have been described elsewhere.30,31 Depth profiles of Raman
spectra were measured at 5-mm intervals from the skin surface at 30, 35, 40,
45 and 50 mm below the skin surface. An average of 8 profiles (totaling to 40
Raman spectra) from different areas of the thenar eminence were measured
per patient. Raman spectra were recorded in the spectral region at 400 to
1,800 cm21 with a 785-nm laser. Laser power on the skin was 25 mW. Levels
of skin constituents relative to keratin were determined from the Raman spectra
by means of classical least-squares fitting. Details of the method have been de-
scribed elsewhere.30,31 Briefly, reference spectra of keratin, NMF, urocanic
acid, lactate, urea, ceramide, and cholesterolwere fitted to the individual Raman
spectra from the skin. The combination of these reference spectra provides an
adequate model for in vivo Raman spectra of normal human SC. A spectrum
of reagent-grade L-tyrosine (Sigma-Aldrich, Zwijndrecht, The Netherlands)
was added to this set of reference-fit spectra to enabledeterminationof increased
tyrosine levels. The resultingfit coefficients represent the relative proportions in
which the skin constituents contribute to the totalRamanskin spectrum.The ref-
erence spectrum of NMF had been constructed from the weighted sum of the
spectra of its dominant constituents (pyrrolidone carboxylic acid, ornithine, ser-
ine, proline, glycine, histidine, and alanine). All concentrations of skin constit-
uents relative to keratin were calculated from the recorded Raman spectra by
using SkinTools 2.0 (River Diagnostics B.V., Rotterdam, The Netherlands);
NMF levels derived from the individual Raman spectra were used to assess in-
trapatient variation inNMF. TheseNMF levelswere then averaged to obtain the
meanNMF level per patient.Of the 135 subjectswho participated in the study, 3
patients were unable to fully cooperate with the Ramanmeasurement, and their
results were excluded because of insufficient spectra collection.
The study was conducted in accordance with the Declaration of Helsinki
andwas approved by the Research Ethics Committee of Our Lady’s Children’s
Hospital, Dublin. Written informed consent was obtained from all patients or
their parents.
Statistical methods
Patients were characterized, a priori, into 3 genotypes (FLG1/1, FLG1/2,
and FLG2/2), as described in the methods. The designation FLG-associated
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1/2 andFLG2/2),
whereas non–FLG-associated AD (ADNON-FLG) are FLG
1/1. The data were
characterized as having either a normal or a skewed distribution. Positively
skewed data were log transformed. Box and whiskers plots showing the me-
dian value with interquartile range (25th-75th box length) of variables were
constructed for the 3 FLG genotypes (FLG2/2, FLG1/2, and FLG1/1).
ANOVA was used to compare means among the 3 genotype subgroups and
presented as means with SDs and 95% CIs. Homogeneity of variances
was tested by using the Levine statistic. A post hoc Tukey analysis for
multiple comparisons was performed to examine pairwise differences among
the 3 genotype subgroups.Mean differences for each pairwise comparisonwas
presented together with a 95% CI of the mean difference.
Nonparametric receiver operating characteristic (ROC) curves, which plot
sensitivity against 12specificity, were constructed to examine the utility of
Raman spectroscopy to, in the first instance, differentiate between ADFLG and
ADNON-FLG.We then sought to further determine whether, within the FLG-as-
sociated AD group, ROC curve analysis could determine an NMF cutoff point
to predict homozygous or heterozygous subjects (FLG2/2 vs FLG1/2). Areas
under the curve (AUCs) with 95% CIs are presented. The cutoff for maximal
sensitivity and specificity was deduced from the graphic output. Sensitivity
and specificity for our dataset, based on the ROC output, are also presented
to provide a preliminary indication of the clinical utility of Raman spectros-
copy as a novel technique to distinguish FLG genotypes in patients with AD.
However, further evaluation of Raman spectroscopy will be required in differ-
ent well-characterized populations of patients with AD and healthy subjects.
HLP was scored clinically as absent (0) mild (1), or severe (2). For
statistical analysis, HLP was dichotomized to no evidence of hyperlinearity
(clinical score 0) versus any hyperlinearity (clinical scores of 1 or 2). The k
statistic was used tomeasure agreement between clinical scores of HLP and an
NMF cutoff of 1.07. Where the observed agreement between scores is better
than the degree of agreement expected by chance alone, k is scored from 0 to
1.0, with 1.0 representing perfect agreement. A kvalue of less than 0.2 is poor,
a score of 0.2 to 0.4 is fair, 0.4 to 0.6 is considered moderate agreement, 0.6 to
0.8 is considered good agreement, and greater than 0.8 is considered excellent
agreement.32 Data were analyzed with SPSS software (version 15; SPSS, Inc,
Chicago, Ill). Significance was set at the 5% level.RESULTS
Clinical characteristics and summary data of the study cohort
are outlined in Table I. NMF levels assessed by means of Raman
spectroscopy for subjects according to final FLG genotype (final
genotype after full screening) are shown in Fig 1. In each pairwise
comparison of the 3 genotypes, there is a statistically significant
difference in NMF values (P < .001, ANOVA, Tukey post hoc
analysis; Table II). IgE levels were not normally distributed. After
log transformation of IgE data, there was no statistically signifi-
cant difference in IgE values among the 3 FLG mutation sub-
groups (P < .48, Table I).
Within the FLG1/1 and FLG1/2 genotype subgroups, 13 sub-
jects had significantly outlying values with significantly lower
NMF values compared with others who shared these genotypes
(Fig 2). We hypothesized that these outlying values were sugges-
tive of additional undetected FLG mutations. These 13 subjects
were therefore fully sequenced for potential additional mutations.
After full sequencing of these 13 subjects, 5 novel mutations
(R3418X, G1138X, S1040X, 10085delC and L2933X) were de-
tected. The entire collection was then rescreened to include 11
mutations (6 on initial screening plus these 5 additional muta-
tions); however, no additional patients were found to harbor these
novel rare mutations. NMF values by genotype after this addi-
tional screening are plotted in histogram format in Fig 3. Within
FLG genotype subgroups, a range of values was seen; these values
approximate to a normal distribution in each of the 3 genotypesubgroups. The new mutations increased the percentage of pa-
tients with 1 or more FLG mutations in the collection to 59.8%
(18.2% FLG2/2, 41.7% FLG1/2, and 40.2% FLG1/1; Table I).
NMF values predict FLG genotype in patients with
moderate-to-severe AD
ROC curves were constructed to examine the discriminatory
power of Raman-determined NMF. From a clinical decision
tree, patients were initially grouped as ADFLG and ADNON-FLG
(FLG1/1). The discriminatory power of Raman-determined
NMF here was high, with an AUC on ROC analysis of 0.95
(95% CI, 0.91-0.99; Fig 4). The optimal cutoff value for NMF
was 1.07, which would equate to a sensitivity of 98.73% and a
specificity of 86.89% extrapolated from our ROC analysis.
With the ADFLG group of children, NMF values also distin-
guished between FLG1/2 and FLG2/2 subjects, with an ROC
AUC of 0.85 (95% CI, 0.77-0.93; see Fig E1 in this article’s
Online Repository at www.jacionline.org). This sensitivity and
specificity is presented to suggest the probable utility of Raman
spectroscopy as a novel diagnostic technique in patients with
AD and is not presented as a test for the goodness of fit of the
model.Tyrosine peaks on Raman microspectroscopy
predict FLG2/2 genotype
The Raman spectra collected in the study revealed a distinct
signal profile in a subset of patients subsequently identified by
matching of in vitroRaman spectra of the amino acid tyrosine. Ty-
rosine levels 5 SDs greater than the normal tyrosine level mea-
sured in FLG1/1 subjects were identified as increased. Above
this threshold, distinct tyrosine peaks could be visually identified
in the corresponding Raman spectra. Tyrosine peaks were present
in 19 (79%) of 24 of the patients who had 2 FLGmutations (Table
I) and absent from all but 1 FLG1/1 subject, who also had an out-
lying lowNMF level (Fig 5), suggesting an undetected genetic de-
fect in FLG. The optimum NMF cutoff to correlate with tyrosine
peaks was 0.831 (AUC, 0.81; 95%CI, 0.73-0.89), which is similar
to the cutoff that distinguishes the FLG2/2 from the FLG1/2 pop-
ulations (data not shown).TEWL in patients with moderate-to-severe AD does
not discriminate between FLG genotype subgroups
There was no difference in mean TEWL levels among the 3
FLG genotype subgroups (Table I). TEWL did not distinguish
FLG genotype status in patients with AD (TEWL AUC, 0.583;
95% CI, 0.48-0.699; ROC curve not shown).NMF values and palmar hyperlinearity scores
There was good agreement between clinical assessment of
palmar hyperlinearity and anNMF cutoff of 1.07 (k5 0.71). Thus
palmar hyperlinearity might help distinguish patients with AD
into those with 1 or more FLG mutations versus those with none.
Clinical assessment is not as accurate as Raman spectroscopy in
distinguishing the 3 FLG genotypes. The NottinghamEczema Se-
verity Score did not segregate with FLG genotype in this collec-
tion (data not shown), suggesting that the spectrum of AD severity
within this moderate-to-severe collection is independent of FLG
genotype.
TABLE I. Cohort characteristics according to final genotype
Final FLG
genotype*y
All mutations
combined, no. (%)
Age (y),
mean (SD)
Male sex,
no. (%)
NESS,z
mean (SD)
Palmar
hyperlinearity
scorez
TEWL (g/m2/h),
mean (SD)
NMF (AU),
mean (SD)
Tyrosine
peaks,
no. (%)
Log IgE#
mean (SD)
Screened§ n 5 132 n 5 132 n 5 132 n 5 132 n 5 131 n 5 102 n 5 132 n 5 132 n 5 129
1/1 53 (40.15) 8.43 (3.76) 32 (60.3) 12.40 (2.39) 0: 36 15.54 (9.34), n 5 41 1.31 (0.24) 1 (1.89) 6.89 (2.29)
1: 10
2: 7
n 5 53
1/2 55 (41.66) 8.2 (4.12) 32 (58.2) 11.28 (2.80) 0: 8 15.59 (6.72), n 5 44 0.80 (0.21) 10 (18.18) 6.56 (1.78)
1: 23
2: 23
n 5 54
2/2 24 (18.18) 8.83 (4.16) 15 (62.5) 12.13 (2.52) 0: 0 17.35 (7.37), n 5 17 0.57 (0.15) 19 (79.16) 7.11 (1.50)
1: 1
2: 23
n524
P value 2 .84k .97{ .07k 2 .70k <.0001k <.0001{ .48k
AU, Arbitrary units.
*Final FLG status after rescreening cohort for all mutations (FLG status before detection of novel mutations: FLG1/1, 41.7%; FLG1/2, 43.2%; and FLG2/2, 15.1%).
1/1, No FLG mutation; 1/2, 1 FLG mutation; 2/2, 2 FLG mutations.
NESS, Nottingham Eczema Severity Score. Palmar hyperlinearity score: 0, no hyperlinearity; 1, intermediate; 2, marked.
§Hyperlinearity scoring and TEWL data are not available for 1 and 30 subjects, respectively.
kComparison of means among the 3 groups of FLG mutations using ANOVA.
{Comparison of proportions using x2 test for comparison of a 2 3 3 contingency table.
#IgE data were positively skewed. The mean of the log-transformed data is presented.
FIG 1. Box and whiskers plot of NMF by FLG genotypes (final genotype
after full screening) showing the median (midline) and interquartile range
corresponding to the length of the box.
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A primary aim of this study was to investigate the utility of in
vivomeasurements of the SC to differentiate between FLG geno-
types within patients with AD. Second, by making use of a very
well-genotyped collection, we sought to determine whether
FLG genotype influenced TEWL in patients with established
moderate-to-severe AD. These results establish that the biochem-
ical composition of the SC and palmar hyperlinearity associate
with FLGmutation status, allowing rapid stratification of AD en-
dotypes. Furthermore, we conclude that the degree of barrier de-
fect, as measured by TEWL, in the clinically unaffected skin of
patients with established AD is not influenced by FLG genotype.
The clinical utility of Raman-determined NMF is powerfully
illustrated in the ROC curve analysis, which has an AUC of 0.95
(95% CI, 0.91-0.99) to discriminate between the ADFLG and
ADNON-FLG groups. In addition, NMF can distinguish from hetero-
zygousFLGmutations. In otherwords, this technique allows segre-
gation ofAD intoFLG genotypes (1/1,1/2, and2/2) with such
high specificity that it can accuratelypredictFLGgenotype.Even in
this relatively small patient population,meanNMFwas statistically
different between each of the 3 subpopulations (post hoc Tukey,
Table II) Further validation of Raman-determined NMF is required
in patients withwell-characterizedAD and healthy populations be-
fore this novel technique can be considered for clinical use.
The observed interindividual variation in NMF results within
the mutation groups approximates to a normal distribution (Fig 3)
that might be caused by environmental, genetic, or immunologic
modifiers of FLG expression, including posttranslational process-
ing. Homeostatic mechanisms or genetic mechanisms, such as the
effects of copy number variation, small gene deletions, cytokine
modulation of FLG expression, or upregulation of additional
sources of NMF constituents, such as eccrine-derived lactate
and glycerol, might account for differences in NMF levels within
genotype groups. Modifying genes involved in filaggrin-
processing pathways are likely to additionally contribute to thisvariation.20 The strong relationship between FLGmutation status
and NMF implies that the role of other histidine-rich barrier pro-
teins, such as the S100-fused proteins, including filaggrin-2 and
hornerin, that are thought to have synergistic roles with filaggrin,
including contribution to NMF levels,33-35 are unlikely to play a
major role in the total NMF seen in AD patients.
The strong predictive value of a tyrosine signal in the SC of
subjects with FLG mutations identifies a potential biomarker in
TABLE II. ANOVA showing a statistically significant difference in NMF among the 3 FLG genotype subgroups together with 95% CIs
Genotype No. Mean NMF 95% CI Comparison genotype Mean difference 95% CI mean difference P value*
FLG1/1 53 1.31 6 0.24 1.24 to 1.37 FLG1/2 0.51 0.40 to 0.60 <.001
FLG2/2 0.74 0.62 to 0.87 <.001
FLG1/2 55 0.80 6 0.21 0.74 to 0.86 FLG1/1 20.51 20.60- to 20.41 <.001
FLG2/2 0.24 0.11 to 0.36 <.001
FLG2/2 24 0.57 6 0.15 0.50 to 0.63 FLG1/1 20.74 28.86 to 20.61 <.001
FLG1/2 20.24 20.36 to 20.11 <.001
A post hoc analysis with Tukey correction shows a statistically significant difference in mean NMF between each pairwise comparison for the 3 FLG genotype subgroups.
*Tukey multiple comparisons.
FIG 2. NMF cloud plot of values subcategorized after initial screening of 6
prevalent mutations. Circles indicate outliers who were rescreened for ad-
ditional mutations. Colors indicate the final genotype after full screening.
For each group, the number of patients and average NMF level (mean 6
SD) are indicated in the figure. Group comparisons showing means and
standard deviations by using ANOVA are presented in the text. a.u.,
Arbitrary units.
FIG 3. Histogram of all nonaveraged NMF values subcategorized according
to corrected mutational status. Blue bars are FLG1/1 subjects, green bars
are FLG1/2 subjects, and red bars are FLG2/2 subjects. For each group,
the number of Raman measurements and the average NMF level
(mean 6 SD) are indicated in the figure. FLG genotype group sizes are as
follows: FLG2/2, 24; FLG1/2, 55; FLG1/1, 53. a.u., Arbitrary units.
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however, the linker segments and carboxyl-terminal domains of
profilaggrin contain dense and highly conserved tyrosine-rich
motifs.11,12,36 In normal SC only tyrosine incorporated in pro-
teins, predominantly keratin, contributes to the overall Raman
spectrum of skin; unbound tyrosine is usually not detectable.
The consistent observation of the presence of tyrosine peaks in
homozygous FLG mutation carriers might relate to altered bio-
synthetic pathways, such as limited proteolysis of profilaggrin
or aberrant intermediate processing species, degraded through
alternative pathways. The presence of tyrosine is independent
of disease severity or mutation location.
Palmar and plantar hyperlinearity is a consistent clinical
finding in the monogenic FLG disease ichthyosis vulgaris, and
in keeping with a semidominant trait, intermediate hyperlinearity
is thought to be associated with heterozygosity for FLG muta-
tions; hyperlinearity has been associated as a significant finding
in patients with FLG-related AD.37-40 Brown et al41 have recently
shown significant association of palmar hyperlinearity with FLG-
null mutations in a population-based cohort.41 Our finding that
FLG status and NMF segregate with palmar hyperlinearity in pa-
tients with moderate-to-severe AD further validates the impor-
tance of this clinical sign in AD phenotypes.
Evidence from bothmolecular genetics and functional analyses
strongly supports a skin barrier defect as a feature of both lesional
and nonlesional skin in patients with AD.42-44 Increased mean
baseline TEWL levels, reflecting a dysfunction of the inside-outepidermal permeability barrier in the clinically uninvolved skin
of patients with AD, have been shown in many previous stud-
ies.45-47 The concept of an inherent skin barrier defect in both le-
sional and nonlesional skin from patients with is further supported
by other methodologies, including recent data by Jakasa et al43
showing enhanced uptake of entire series of polyethylene glycols
covering molecular weights in the range 150 to 590 daltons in
nonlesional skin of patients with AD. Hata et al, using a photoa-
coustic spectroscopic system, showed enhanced penetration
of both lipophilic and hydrophilic dye through clinically normal
skin of patients with AD compared with that seen in control
subjects.42-44
Previous investigators have reported contrasting findings on the
influence of FLG mutation status on the inside-out barrier, as
measured by TEWL in patients with AD; however, these studies
were restricted by small sample size and possibly confounded by
the technical limitations of disclosure of full FLG polymorphism
status in the populations studied.10,48 A French study including a
small number of FLG mutation carriers suggested that TEWL in
patients with ADwas not influenced by FLG status.49 Here, in our
much larger collection of comprehensively genotyped patients
with moderate-to-severe AD, TEWL again showed no discern-
able difference between FLG genotype subpopulations. These
results suggest that increased TEWL in patients with moderate-
to-severe AD is independent of FLG status and is a common
end point in patients with moderate-to-severe AD. Thus increased
TEWLmight result from the systemic effects of the inflammatory
FIG 4. ROC curve for NMF ADFLG (genotype 1/2 and 2/2) compared with
ADNON-FLG (genotype1/1). The AUC is 0.95 (95% CI, 0.91-0.99). The optimal
cutoff point for mean NMF to distinguish ADFLG from ADNON-FLG was 1.07
arbitrary units.
FIG 5. Cloud plot of NMF values categorized by genotype (final genotype
after full screening). Circles indicate subjects with an increased tyrosine sig-
nal (FLG1/1, n 5 1; FLG1/2, n 5 10; FLG2/2, n 5 19). For each group, the
number of patients and average NMF level (mean 6 SD) are indicated in
the figure. a.u., Arbitrary units.
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tail (ft)mice show a moderate increase in baseline TEWL, a devi-
ation that increases dramatically after allergen priming and the
subsequent secondary inflammatory response.8 In these mice, al-
though FLG deficiencymight of itself lead to an inside-out barrier
defect barely measureable by increased TEWL, the subsequent
marked increase in TEWL appears to be driven by the secondary
immunologic response.
Within this collection, no effect was seen for FLG and disease
severity or total serum IgE level; however, this case series is not
the ideal collection to examine this because all cases are moderate
to severe and therefore the full range of severity is not repre-
sented. Further population-based and sufficiently powered studies
should clarify this potential genotype-phenotype correlation.Within patients with AD, Raman signatures of NMF level and
tyrosine predict FLG mutation status, overcoming the need for
technically demanding genotyping, particularly in populations
in which the FLGmutation architecture has not been comprehen-
sively elucidated. This work additionally further informs mecha-
nistic pathways in AD, demonstrating that TEWL in patients with
moderate-to-severe AD is an outcome that is independent of FLG
mutation status and pointing to a complex systemic interplay of
environmental, immunologic, and functional pathways in the gen-
esis of epithelial barrier disruption in patients with AD.
We thank the patients and their families for their involvement in this study.
Key messages
d Raman spectroscopy, specifically NMF analysis, permits
rapid and accurate stratification of FLG-associated ver-
sus non–FLG-associated AD and might be useful as a pre-
dictive test for FLG mutations.
d There is good agreement between FLG mutation status,
NMF, and clinical palmar hyperlinearity scoring in pa-
tients with moderate-to-severe AD. Palmar hyperlinearity
might help to define a clinical and genetic phenotype of
AD.
d Within patients with moderate-to-severe AD, TEWL
levels do not segregate with FLG genotype, suggesting
that FLG mutations are neither necessary nor sufficient
to fully explain this inside-out barrier defect in estab-
lished AD.
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FIG E1. ROC curve for NMF values to distinguish FLG1/2 subjects from
FLG2/2 subjects in the ADFLG group. AUC is 0.85 (95% CI, 0.76-0.93), with
a sensitivity of 96% and a specificity of 66.77% at a cutoff of 0.767 arbitrary
units.
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